Nyxoah (NYXH) Q4 2025 Earnings Call Transcript

Nyxoah reported Q4 U.S. revenue of $4.5M and full-year net revenue of €10.0M, up 122% YoY following August FDA approval of Genio; Q4 gross margin was 64% and full‑year gross margin 63%. Full-year operating loss widened to €83.5M (from $58.8M in 2024) as U.S. commercialization ramped, while year-end cash and financial assets totaled €48.0M and management expects a near-term cash burn of ~€20.0M/quarter, with runway extended into 2027. Management provided 2026 guidance calling for U.S. net revenue to rise ~25% sequentially and slight gross margin improvement, and highlighted reimbursement clarity (CMS interim C-code 8011 facility fee set at $31,526) and upcoming ACCESS 12‑month data with a PMA supplement pathway targeting early‑2027 label expansion.

Analysis

The most important structural shift here is that coding parity removes a facility-fee lever that could have advantaged or disadvantaged early entrants; competition will therefore migrate to surgeon workflow, patient selection and O.R. economics. That favors the company that can demonstrably shorten procedure time, reduce downstream resource use and limit re‑operations — not necessarily the lowest quoted implant price. Expect hospital procurement decisions to increasingly be driven by total cost of episode metrics (LOS, re-admit risk, OR minutes) rather than headline device cost.

Operationally the rollout is a classic commercialization cadence: training → VAC approvals → first-case conversion → steady-state utilization. The second-order risk is conversion velocity: a backlog of trained surgeons does not equal durable procedure volume if VAC cycle times, OR scheduling constraints, or competing device inventory management slow conversion. Two binary milestones will reprice optionality — the mid‑year clinical readout that expands label/indication and the next‑generation disposable that meaningfully lowers recurring cost — and both have asymmetric outcomes for margins and capital needs.

From a competitive angle, an imminent incumbent launch is a two-edged sword: it can commoditize the category and compress pricing, but it also grows the reference base and referrals to HGNS therapy overall, which benefits an early mover with differentiated clinical claims. The clearest balance-sheet tail risk is slower-than-expected utilization forcing nearer-term fundraising; conversely, a clean clinical readout plus manufacturability of the cheaper disposable patch is a steep margin convexity that justifies patient-timing optionality in public equities and options strategies.

Key Decisions for Investors

• Long NYXH (size 1–3% portfolio) on any >20% post‑announcement pullback; hold through the mid‑year clinical readout and the next‑gen patch commercialization window. Risk: procedural conversion stalls or additional capital raise; Reward: asymmetric uplift from label expansion and margin step.
• Buy NYXH 12–18 month call spread (debit capped) to capture binary upside from the clinical readout and Genio 2.x margin improvement — long-dated calls hedged by selling a higher strike to finance premium. Structure entry around 6–8 weeks before the readout to avoid early premium inflation; max loss = premium, target 2–4x return if catalysts succeed.
• Relative trade: go long NYXH / short LIVN (equal notional, 6–12 month horizon) to express conviction in differentiated technology uptake. Rationale: capture share reallocation if surgeon preference, single-incision workflow and margin tailwinds favor Genio; hedge size to limit idiosyncratic regulatory or execution risk at either name.
• Event hedge: if you own NYXH equity and are worried about a disappointment, buy short-dated puts covering 20–30% of the position into the clinical readout window rather than selling shares — cheaper tail protection that preserves upside while capping downside during the binary event.